Viridian Therapeutics, Inc. VRDN Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s investment proceeds?
- Viridian Therapeutics, Inc. (VRDN) reported investment proceeds of $168.6M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Viridian Therapeutics, Inc.'s investment proceeds decreased by 1.6% year-over-year, from $171.39M to $168.6M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s investment proceeds has grown at a 47.4% compound annual growth rate (CAGR), from $114.9M to $542.21M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.